|
WU-MDACC Inter-Institutional Molecular Imaging Center
|
5P50CA094056-13
|
$1,336,045
|
$80,163
|
PIWNICA-WORMS, David
|
WASHINGTON UNIVERSITY
|
|
Vaccine Immunotoxin and Radioimmunotherapy of Primary and Metastatic CNS Tumors
|
5P01CA154291-02
|
$3,054,903
|
$641,530
|
BIGNER, DARELL
|
DUKE UNIVERSITY
|
|
University of Texas SPORE in Lung Cancer
|
3P50CA070907-15S1
|
$560,104
|
$112,021
|
MINNA, JOHN
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Understanding and Eliminating Oncogenic EGFR Signaling in Malignant Glioma
|
5U01CA141556-05
|
$619,594
|
$154,899
|
Charest, Alain
|
TUFTS MEDICAL CENTER
|
|
UCLA Tumor Immunology Training Program
|
3T32CA009120-37S1
|
$38,598
|
$7,720
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
UCLA Tumor Immunology Training Program
|
5T32CA009120-37
|
$465,035
|
$93,007
|
TEITELL, MICHAEL
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Treatment of HPV+ Head and Neck Cancer with siRNA Nanosphere Particles
|
N43CO130077-000
|
$198,141
|
$198,141
|
MACDOUGALL, JOHN
|
AURA BIOSCIENCES, INC.
|
|
Transport of Large Molecules and Viral Vectors in Tumors: Effects of Cytotoxic an
|
5R01CA098706-10
|
$262,036
|
$262,036
|
BOUCHER, YVES
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Transduction of T cells to improve migration to tumor
|
5R01CA116206-09
|
$323,570
|
$323,570
|
HWU, PATRICK
|
UT MD ANDERSON CANCER CTR
|
|
TRAINING IN CANCER BIOLOGY AND TRANSPLANTATION
|
5T32CA009515-29
|
$638,503
|
$638,503
|
APPELBAUM, FREDERICK
|
UNIVERSITY OF WASHINGTON
|
|
TRAIL-expressing Recombinant Adenovirus Based Immunotherapy for RCC
|
5R01CA109446-11
|
$242,926
|
$242,926
|
Griffith, Thomas
|
UNIVERSITY OF MINNESOTA
|
|
Therapeutic vaccination against genital HPV infection
|
1R43CA174436-01A1
|
$288,194
|
$288,194
|
Chang, Yung
|
PAPIVAX, LLC
|
|
Therapeutic Potential of IL-15 Plasmid Delivery to Tumors Using Electroporation
|
5R01CA122518-06
|
$245,531
|
$245,531
|
HELLER, RICHARD
|
OLD DOMINION UNIVERSITY
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
3P50CA083639-14S1
|
$31,250
|
$3,750
|
BAST, ROBERT
|
UT MD ANDERSON CANCER CTR
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Ovarian Cancer
|
5P50CA083639-14
|
$2,082,690
|
$249,923
|
BAST, ROBERT
|
UT MD ANDERSON CANCER CTR
|
|
The University of Texas M. D. Anderson Cancer Center SPORE in Melanoma
|
5P50CA093459-09
|
$2,150,500
|
$129,030
|
GRIMM, ELIZABETH
|
UT MD ANDERSON CANCER CTR
|
|
The UCLA Center for In Vivo Imaging in Cancer Biology
|
5P50CA086306-14
|
$1,723,723
|
$206,847
|
Herschman, Harvey
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
The Regulation of Tumor Progression by Endothelial HoxA5
|
5R01CA140655-04
|
$292,312
|
$96,463
|
BOUDREAU, NANCY
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
The in vivo role of the mitochondrial p53 cell death program
|
5R01CA060664-18
|
$250,252
|
$125,126
|
MOLL, UTE
|
STATE UNIVERSITY NEW YORK STONY BROOK
|
|
The GNAQ pathway as a therapeutic target in uveal melanoma
|
5R01CA142873-04
|
$292,312
|
$96,463
|
BASTIAN, BORIS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
The Antigen Targeting Core
|
ZIC BC 011030
|
$180,813
|
$90,407
|
Parkhurst, Maria
|
CCR (NCI)
|
|
TGFbeta Blockade in MART TCR-Engineered T Cell Melanoma Immunotherapy in Man
|
1R01CA164333-01A1
|
$319,550
|
$159,775
|
Koya, Richard
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Texas Center for Cancer Nanomedicine
|
5U54CA151668-04
|
$1,850,049
|
$777,021
|
Gorenstein, David
|
UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON
|
|
Telomere Biology
|
ZIA BC 011519
|
$1,237,347
|
$24,747
|
Cooper, Julia
|
CCR (NCI)
|
|
TCR Gene Modified T Cells for Adoptive Immunotherapy
|
5P01CA154778-03
|
$3,141,645
|
$1,727,905
|
NISHIMURA, MICHAEL
|
LOYOLA UNIVERSITY CHICAGO
|
|
Targeting Translation Control in Malignant Glioma
|
5R01CA124756-07
|
$238,436
|
$238,436
|
GROMEIER, MATTHIAS
|
DUKE UNIVERSITY
|
|
Targeting the let-7-HMGA2 Network in Metastatic Progression in Pancreatic Cancer
|
5R03CA164677-02
|
$76,140
|
$38,070
|
RESAR, LINDA
|
JOHNS HOPKINS UNIVERSITY
|
|
Targeting Oncogene Expression to Skin in Transgenic Mice
|
5R01CA052607-21
|
$449,076
|
$449,076
|
Roop, Dennis
|
UNIVERSITY OF COLORADO DENVER
|
|
TARGETING EPIGENOMIC SIGNATURES IN NON-HODGKIN LYMPHOMA FOR NOVEL THERAPEUTICS
|
5R01CA156690-04
|
$284,934
|
$284,934
|
Oltz, Eugene
|
WASHINGTON UNIVERSITY
|
|
Targeted-and Image-Based Adenovirus Cancer Therapeutic Vectors
|
5R01CA154697-03
|
$449,047
|
$449,047
|
Curiel, David
|
WASHINGTON UNIVERSITY
|
|
Targeted therapy of ALL with gene-modified central memory T cells
|
5R01CA136551-05
|
$508,741
|
$254,371
|
Riddell, Stanley
|
FRED HUTCHINSON CAN RES CTR
|
|
Targeted theranostic microbubble vectors for transcription factor decoy delivery
|
5R21CA167373-02
|
$187,225
|
$187,225
|
VILLANUEVA, FLORDELIZA
|
UNIVERSITY OF PITTSBURGH
|
|
Targeted nanoparticle gene therapy for lung cancer
|
1U43CA165462-01A1
|
$190,353
|
$190,353
|
Jouhikainen, Taneli
|
SAVARA, INC.
|
|
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
|
5R01CA157537-03
|
$298,427
|
$298,427
|
PANG, QISHEN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Targeted Chemoprevention for Melanoma
|
5R01CA136667-04
|
$382,639
|
$382,639
|
ROBERTSON, GAVIN
|
PENNSYLVANIA STATE UNIVERSITY
|
|
Synergistic chemo-siRNA combination therapy
|
5R01CA158300-03
|
$350,134
|
$350,134
|
WIENTJES, M
|
OPTIMUM THERAPEUTICS, LLC
|
|
Suppression of BCR-ABL by siRNA-loaded Nanoparticles for the Treatment of CML
|
1F31CA174298-01A1
|
$42,232
|
$42,232
|
Gavrilov, Kseniya
|
YALE UNIVERSITY
|
|
Sten Cell Gene Therapy of Breast Cancer
|
5R01CA136487-05
|
$295,150
|
$295,150
|
LIEBER, ANDRE
|
UNIVERSITY OF WASHINGTON
|
|
Stem Cell-Engineered Tumor Immunity in Man
|
5P01CA132681-04
|
$2,716,765
|
$2,363,586
|
BALTIMORE, DAVID
|
CALIFORNIA INSTITUTE OF TECHNOLOGY
|
|
SPORE: Brain Tumor SPORE Grant
|
2P50CA097257-11A1
|
$2,150,500
|
$107,525
|
BERGER, MITCHEL
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
SPORE In Prostate Cancer
|
3P50CA058236-18S1
|
$1,233,307
|
$246,661
|
NELSON, WILLIAM
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE in Prostate Cancer
|
3P50CA090386-10S1
|
$48,038
|
$3,363
|
Catalona, William
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
SPORE in Prostate Cancer
|
5P50CA090386-10
|
$2,150,501
|
$150,535
|
Catalona, William
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
SPORE In Prostate Cancer
|
5P50CA092629-13
|
$1,871,390
|
$205,853
|
SCHER, HOWARD
|
SLOAN-KETTERING INST CAN RES
|
|
SPORE in Lymphoma
|
5P50CA126752-07
|
$2,150,500
|
$516,120
|
Heslop, Helen
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Genitourinary Cancer
|
5P50CA091846-12
|
$1,899,920
|
$189,992
|
DINNEY, COLIN
|
UT MD ANDERSON CANCER CTR
|
|
SPORE in Cervical Cancer
|
3P50CA098252-10S1
|
$111,720
|
$14,524
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
SPORE in Cervical Cancer
|
5P50CA098252-10
|
$2,150,500
|
$279,565
|
WU, TZYY-CHOOU
|
JOHNS HOPKINS UNIVERSITY
|
|
Somatic Cell Transfer to Model Medulloblastoma in Mice
|
5R01CA108622-09
|
$230,505
|
$230,505
|
FULTS, DANIEL
|
UNIVERSITY OF UTAH
|
|
Sleeping Beauty Mediated Therapy for Alpha V Beta 6-Expressing Pancreatic Cancer
|
1R43CA176957-01
|
$200,244
|
$100,122
|
Hyland, Kendra
|
DISCOVERY GENOMICS, INC.
|
Total relevant funding to Gene Therapy for this search: $51,944,422
|